Use of bioavailability data by practitioners. I: pitfalls in interpreting the data.
Potential pitfalls in evaluating bioavailibility data are presented.  These pitfalls are involved with interpretation of the therapeutic significance of the data, the methodology of the bioavailibility study and presentation of data.  Specific information which should be requested from manufacturers for proper evaluation of bioavailibility data is given.
D000667:Ampicillin / Q000627:therapeutic use; D001682:Biological Availability; D001702:Biopharmaceutics; D004077:Digoxin / Q000627:therapeutic use; D004358:Drug Therapy; D006801:Humans; D007408:Intestinal Absorption; D012107:Research Design
D004077:Digoxin; D000667:Ampicillin